Literature DB >> 28278306

Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3.

Yu-Hung Chang1, Der-Wei Hwu1, Wei-Pin Kao2, Yau-Jiunn Lee1.   

Abstract

Entities:  

Year:  2017        PMID: 28278306      PMCID: PMC5734220          DOI: 10.1900/RDS.2016.13.212

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


× No keyword cloud information.
  15 in total

Review 1.  By Jove! What is a clinician to make of JUPITER?

Authors:  Sanjay Kaul; Ryan P Morrissey; George A Diamond
Journal:  Arch Intern Med       Date:  2010-06-28

2.  Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; H Amy Xia; Thomas Liu
Journal:  Biometrics       Date:  2011-09-28       Impact factor: 2.571

3.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 4.  Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

Authors:  Michel de Lorgeril; Patricia Salen; John Abramson; Sylvie Dodin; Tomohito Hamazaki; Willy Kostucki; Harumi Okuyama; Bruno Pavy; Mikael Rabaeus
Journal:  Arch Intern Med       Date:  2010-06-28

5.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

6.  Rosuvastatin in older patients with systolic heart failure.

Authors:  John Kjekshus; Eduard Apetrei; Vivencio Barrios; Michael Böhm; John G F Cleland; Jan H Cornel; Peter Dunselman; Cândida Fonseca; Assen Goudev; Peer Grande; Lars Gullestad; Ake Hjalmarson; Jaromir Hradec; András Jánosi; Gabriel Kamenský; Michel Komajda; Jerzy Korewicki; Timo Kuusi; François Mach; Vyacheslav Mareev; John J V McMurray; Naresh Ranjith; Maria Schaufelberger; Johan Vanhaecke; Dirk J van Veldhuisen; Finn Waagstein; Hans Wedel; John Wikstrand
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

7.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Jennifer B Green; M Angelyn Bethel; Paul W Armstrong; John B Buse; Samuel S Engel; Jyotsna Garg; Robert Josse; Keith D Kaufman; Joerg Koglin; Scott Korn; John M Lachin; Darren K McGuire; Michael J Pencina; Eberhard Standl; Peter P Stein; Shailaja Suryawanshi; Frans Van de Werf; Eric D Peterson; Rury R Holman
Journal:  N Engl J Med       Date:  2015-06-08       Impact factor: 91.245

8.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Authors:  Luigi Tavazzi; Aldo P Maggioni; Roberto Marchioli; Simona Barlera; Maria Grazia Franzosi; Roberto Latini; Donata Lucci; Gian Luigi Nicolosi; Maurizio Porcu; Gianni Tognoni
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Salim Yusuf; Jackie Bosch; Gilles Dagenais; Jun Zhu; Denis Xavier; Lisheng Liu; Prem Pais; Patricio López-Jaramillo; Lawrence A Leiter; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Alexander Parkhomenko; Katalin Keltai; Matyas Keltai; Karen Sliwa; Ron J G Peters; Claes Held; Irina Chazova; Khalid Yusoff; Basil S Lewis; Petr Jansky; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Gregorio Sanchez-Vallejo; Robert McKelvie; Janice Pogue; Hyejung Jung; Peggy Gao; Rafael Diaz; Eva Lonn
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

10.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

View more
  1 in total

1.  Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes.

Authors:  Clara Ruiz-Fernández; María Gonzalez-Rodríguez; Vera Francisco; Ibraheem M Rajab; Rodolfo Gómez; Javier Conde; Francisca Lago; Jesús Pino; Ali Mobasheri; Miguel Angel Gonzalez-Gay; Antonio Mera; Lawrence A Potempa; Oreste Gualillo
Journal:  Lab Invest       Date:  2021-03-25       Impact factor: 5.662

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.